CADL (Candel) קצב צמיחת רווח למניה בשנה הנוכחית

Candel Therapeutics (CADL) is integrating ESG principles into the development of anticancer immunotherapies by reducing laboratory waste. On GURU.Markets, the annual earnings per share trend shows that the current metric is -80.00. The robotization of drug synthesis is accelerating development, although physicians remain indispensable. Meanwhile, the company's eco-policy remains formal, limited to digital documentation and the monitoring of chemical disposal.

The eps_yy_co metric measures the annual percentage change in earnings per share, reflecting the efficiency of profit generation or the rate of loss reduction relative to the previous year. By analyzing the relative EPS YoY dynamics, an investor can see the impact of cost management for clinical trials and grants at Candel Therapeutics (CADL), which is critical for assessing the company's financial stability prior to the commercialization stage.